$106.11 -0.6 -0.6%
Last Trade - 08/03/21
| Market Cap | £135.55bn |
| Enterprise Value | £191.68bn |
| Revenue | £33.13bn |
| Position in Universe | 54th / 6668 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 22,859 | 25,638 | 28,216 | 32,753 | 33,266 | 45,804 | 53,766 | 57,046 | +14.9% | ||
| +151.5 | +13.6 | +4.5 | +59.2 | -8.3 | -36.4 | +233.5 | +11.7 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | April 10, 2012 |
| Public Since | January 2, 2013 |
| No. of Shareholders: | 47,754 |
| No. of Employees: | 47,000 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | New York Stock Exchange |
| Shares in Issue | 1,765,881,690 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 N Waukegan Rd, NORTH CHICAGO, 60064-1802, United States |
| Web | https://www.abbvie.com/ |
| Phone | +1 847 9327900 |
| Contact | () |
| Auditors | Ernst & Young LLP |
As of 08/03/21, shares in Abbvie Inc are trading at $106.11, giving the company a market capitalisation of £135.55bn. This share price information is delayed by 15 minutes.
Shares in Abbvie Inc are currently trading at $106.11 and the price has moved by 19.47% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abbvie Inc price has moved by -14.59% over the past year.
Of the analysts with advisory recommendations for Abbvie Inc, there are there are currently 6 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Abbvie Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Abbvie Inc is scheduled to issue upcoming financial results on the following dates:
The Abbvie Inc dividend yield is 4.45% based on the trailing twelve month period.
Last year, Abbvie Inc paid a total dividend of 4.72, and it currently has a trailing dividend yield of 4.45%. Looking ahead, shares in Abbvie Inc are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-14.
Abbvie Inc are due to go ex-dividend on 2021-04-14 and the next dividend pay date is 2021-05-14. The historic dividend yield on Abbvie Inc shares is currently 4.45%.
To buy shares in Abbvie Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Abbvie Inc are currently trading at $106.11, giving the company a market capitalisation of £135.55bn.
Here are the trading details for Abbvie Inc:
Based on an overall assessment of its quality, value and momentum, Abbvie Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Abbvie Inc are currently priced at $106.11. At that level they are trading at 4.37% discount to the analyst consensus target price of 0.00.
Analysts covering Abbvie Inc currently have a consensus Earnings Per Share (EPS) forecast of 12.205 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abbvie Inc. Over the past six months, the relative strength of its shares against the market has been 0.65%. At the current price of $106.11, shares in Abbvie Inc are trading at 8.68% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Abbvie Inc PE ratio based on its reported earnings over the past 12 months is 29. The shares are currently trading at $106.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Abbvie Inc's management team is headed by:
Here are the top five shareholders of Abbvie Inc based on the size of their shareholding:
